SCHEMBL7373583

SCHEMBL7373583

O=C(O)C1=CNC=NC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL584416 0.69 TSHR (0.38)
Hydrochloric Acid SCHEMBL7212773 0.67 BLM (0.40)
SCHEMBL3652674 0.67
SCHEMBL3542843 0.65
Piperazine SCHEMBL6367258 0.61 TSHR (0.37)
SCHEMBL9806461 0.61 TSHR (0.34)
SCHEMBL16961751 0.61 TSHR (0.38)
SCHEMBL8693090 0.61
SCHEMBL28271134 0.60
SCHEMBL7648980 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0202654-A2 5-Carboxy-1,4-dihydropyrimidine derivatives E.R. Squibb &amp; Sons, Inc. (US) 1986-11-26 EP claimed
US-11639350-B2 Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections JANSSEN PHARMACEUTICA NV (BE) 2023-05-02 US disclosed
US-20230083012-A1 DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2023-03-16 US disclosed
CN-114907355-A Dihydropyrimidine compound, preparation method and application thereof 上海维申医药有限公司 2022-08-16 CN disclosed
WO-2022121844-A1 DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海维申医药有限公司 2022-06-16 WO disclosed
CN-109803967-B Dihydropyrimidine compound and preparation method and application thereof 浙江海正药业股份有限公司 2022-05-24 CN disclosed
CN-114174300-A Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases 杨森科学爱尔兰无限公司 2022-03-11 CN disclosed
EP-3658554-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE North & South Brother Pharmacy Investment Company Limited (CN) 2020-06-03 EP disclosed
CN-110809574-A Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection 詹森药业有限公司 2020-02-18 CN disclosed
WO-2019001396-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-01-03 WO disclosed
EP-0994859-A1 COMPOUNDS Astra Aktiebolag (publ) (SE) 2000-04-26 EP disclosed
EP-0993450-A1 NEW COMPOUNDS Astra Aktiebolag (publ) (SE) 2000-04-19 EP disclosed
WO-1999001437-A1 COMPOUNDS ASTRA AKTIEBOLAG (PUBL) (SE) 1999-01-14 WO disclosed
WO-1999001438-A1 NEW COMPOUNDS ASTRA AKTIEBOLAG (PUBL) (SE) 1999-01-14 WO disclosed
US-4918074-A CALCIUM ANTAGONISTS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1990-04-17 US disclosed
EP-0202654-A3 5-CARBOXY-1,4-DIHYDROPYRIMIDINE DERIVATIVES E.R. Squibb &amp; Sons, Inc. (US) 1987-12-16 EP disclosed
EP-0202654-A3 5-CARBOXY-1,4-DIHYDROPYRIMIDINE DERIVATIVES E.R. Squibb &amp; Sons, Inc. (US) 1987-12-16 EP disclosed
EP-0202654-A2 5-Carboxy-1,4-dihydropyrimidine derivatives E.R. Squibb &amp; Sons, Inc. (US) 1986-11-26 EP disclosed
EP-0202654-A2 5-Carboxy-1,4-dihydropyrimidine derivatives E.R. Squibb &amp; Sons, Inc. (US) 1986-11-26 EP disclosed
EP-0163240-A2 Dihydroimidazo[1,2-a]pyrimidine derivatives, methods of preparing said compounds and pharmaceutical compositions constaining said compounds Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1985-12-04 EP disclosed